The quest for the best dual orexin receptor antagonist (daridorexant) for the treatment of insomnia disorders.

We describe our efforts leading to the identification of a promising set of dual orexin receptor antagonists (DORAs) which subsequently went through physiology-based pharmacokinetic and pharmacodynamic modelling 1 and finally led to the selection of daridorexant ( 93 ) currently in phase 3 clinical trials for the treatment of insomnia disorders.
PMID: 32937014 [PubMed - as supplied by publisher]

Source: ChemMedChem - September 15, 2020 Category: Chemistry Authors: Boss C, Gatfield J, Brotschi C, Heidmann B, Sifferlen T, von Raumer M, Schmidt G, Williams JT, Treiber A, Roch C Tags: ChemMedChem Source Type: research